Purple Biotech Ltd. (PPBT)
| Market Cap | 25.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 21.06M |
| Shares Out | 24.36M |
| EPS (ttm) | -1.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138 |
| Open | 1.07 |
| Previous Close | 1.07 |
| Day's Range | 1.00 - 1.10 |
| 52-Week Range | 0.88 - 2.37 |
| Beta | 0.98 |
| Analysts | Strong Buy |
| Price Target | 9.67 (+838.84%) |
| Earnings Date | Nov 21, 2023 |
About PPBT
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for PPBT stock is "Strong Buy." The 12-month stock price forecast is $9.67, which is an increase of 838.84% from the latest price.
News
Purple Biotech Reports Third Quarter 2023 Financial Results
Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1 /2 Do s e Escalation Study Patients ' E nrollment in the Phase 2 Randomized CM24 Pancreatic Cancer T rial A head of T imelines C ...
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
REHOVOT, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harnes...
Purple Biotech Announces $5 Million Registered Direct Offering
REHOVOT, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harne...
Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action
REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harnes...
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
REHOVOT, Israel, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harnes...
Purple Biotech Reports Second Quarter 2023 Financial Results
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 study Clinical data from both studies expected in the coming months Cash runway ext...
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
REHOVOT, Israel, July 11, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harnes...
Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update
Expands p ipeline with a cquisition of n ew tri-specific antibodies D ata readouts for two lead clinical programs expected in 2023
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
New preclinical data from study presented at the American A ssociation for Cancer Research 2023 Annual Meeting , 18 April 2023
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
REHOVOT, Israel, April 18, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, e...
Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
Board of Directors appoints Isaac Israel , Board member and former CEO, as acting CEO Company's business plan and clinical development programs continue as planned
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
REHOVOT, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durabl...
Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results
Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023
Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis
Data demonstrate suppression by CM24 of NET-promoting cancer cell migration and metastasis
Purple Biotech Reports Third Quarter 2022 Financial Results
Well capitalized with cash runway through 2024
Purple Biotech Appoints Lior Fhima as Chief Financial Officer
Seasoned financial executive strengthens management team
Purple Biotech Reports Second Quarter 2022 Financial Results
REHOVOT, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durab...
Purple Biotech Announces Executive Leadership Changes
Gil Efron appointed as Chief Executive Officer
Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile
A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer
Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients
Decision based on positive interim Phase 1b data in pancreatic ductal adenocarcinoma (PDAC) Decision based on positive interim Phase 1b data in pancreatic ductal adenocarcinoma (PDAC)
Purple Biotech Reports First Quarter 2022 Financial Results
REHOVOT, Israel, May 12, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durabl...
Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting
First-in-class monoclonal antibody in combination with Opdivo® (nivolumab) demonstrates strong safety and an initial efficacy profile for PDAC
Purple Biotech Reports Second Half and Full-Year 2021 Financial Results
REHOVOT, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durab...
Purple Biotech Issues Letter to Shareholders
REHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and dur...
Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors
REHOVOT, Israel, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durab...